Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
QNRX 
Quoin Pharmaceuticals Ltd DRC (QNRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: QNRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $40.67
1 Year Target Price $40.67
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -82.01% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.47M USD | Price to earnings Ratio 0.01 | 1Y Target Price 40.67 |
Price to earnings Ratio 0.01 | 1Y Target Price 40.67 | ||
Volume (30-day avg) 2 | Beta 1.85 | 52 Weeks Range 5.01 - 33.53 | Updated Date 09/14/2025 |
52 Weeks Range 5.01 - 33.53 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 958.65 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -69.03% | Return on Equity (TTM) -242.67% |
Valuation
Trailing PE 0.01 | Forward PE - | Enterprise Value -3320257 | Price to Sales(TTM) - |
Enterprise Value -3320257 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.42 | Shares Outstanding 588167 | Shares Floating 4112640 |
Shares Outstanding 588167 | Shares Floating 4112640 | ||
Percent Insiders 0.2 | Percent Institutions 0.16 |
Upturn AI SWOT
Quoin Pharmaceuticals Ltd DRC
Company Overview
History and Background
Quoin Pharmaceuticals, founded in 2018, focuses on developing and commercializing therapeutic products for rare and orphan diseases. The company's initial focus is on Netherton Syndrome and other dermatological conditions.
Core Business Areas
- Drug Development: Quoin's primary business is the research, development, and eventual commercialization of therapies for rare diseases, focusing primarily on dermatological conditions.
Leadership and Structure
The company is led by a team of experienced pharmaceutical executives and scientists. The organizational structure includes departments for research and development, clinical operations, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- QRX003 (Netherton Syndrome): QRX003 is a topical formulation being developed for the treatment of Netherton Syndrome, a rare genetic skin disorder. There is no approved treatment currently. Competitors are companies developing gene therapies or novel biologics for similar skin conditions. Market share is N/A as the drug is still in development.
Market Dynamics
Industry Overview
The pharmaceutical industry focused on rare diseases is growing, driven by increased awareness, regulatory incentives, and advancements in drug development technologies.
Positioning
Quoin is positioned as a specialty pharmaceutical company focused on unmet medical needs in rare dermatological conditions. Its competitive advantage lies in its targeted approach to niche markets with limited treatment options.
Total Addressable Market (TAM)
The TAM for Netherton Syndrome and similar rare skin diseases is estimated to be in the hundreds of millions of dollars. Quoin is positioned to capture a significant share of this market if QRX003 is approved.
Upturn SWOT Analysis
Strengths
- Focus on rare diseases
- Targeted approach to niche markets
- Potential for orphan drug designation and regulatory incentives
- Experienced management team
Weaknesses
- Limited financial resources
- High risk associated with drug development
- Dependence on successful clinical trials
- Small product pipeline
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of product pipeline through acquisitions or licensing
- Further development of the market for rare disease therapies
- Positive clinical trial results
Threats
- Competition from other companies developing therapies for rare diseases
- Regulatory hurdles and delays
- Failure of clinical trials
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- VYNE
- DERM
- ALVR
Competitive Landscape
Quoin faces competition from larger pharmaceutical companies and smaller biotech firms developing therapies for dermatological conditions. Its advantages include a focus on rare diseases and a targeted approach to niche markets. Disadvantages include limited financial resources and a small product pipeline.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the company's progress in advancing its drug candidates through preclinical and clinical development.
Future Projections: Future growth is dependent on the successful development and commercialization of QRX003 and other pipeline candidates. Projections are not available.
Recent Initiatives: Recent initiatives include ongoing clinical trials for QRX003 and efforts to secure partnerships and funding.
Summary
Quoin Pharmaceuticals is a development-stage company focused on rare dermatological diseases. The company's success hinges on the clinical development and commercialization of its lead candidate, QRX003. The company has a narrow pipeline and therefore faces risks if the development of QRX003 is not successful. It needs to obtain additional funding to continue the development of its pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (if available)
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The information provided is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Quoin Pharmaceuticals Ltd DRC
Exchange NASDAQ | Headquaters Ashburn, VA, United States | ||
IPO Launch date 2016-07-29 | Co-Founder, CEO & Chairman Dr. Michael Myers Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://quoinpharma.com |
Full time employees 3 | Website https://quoinpharma.com | ||
Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.